Table 1 ACE-induced CTL from patients with ovarian cancer recognise HER-2/neu peptides

From: Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo

   

HER-2/neu peptides

Effectors a

Melan (927)

Gp (9154)

(9851)

(10952)

(9689)

(9402)

(9435)

(9665)

(9369)

Ova-1

7.0b

8.5

21.5 c

7.6

11.3

8.8

47.6

38.7

39.5

Ova-2

2.5

6.3

8.5

7.2

41.7

12.1

52.7

10.3

35.9

Ova-3

9.0

5.5

6.9

3.9

25.6

3.9

52.8

6.7

30.6

Ova-4

6.5

7.2

10.2

8.3

7.2

10.5

9.3

7.5

3.9

Ova-5

10.2

3.2

5.6

2.5

5.7

9.6

11.2

6.8

7.5

  1. aMEAMNC sensitised in vitro against ACE from autologous HER-2/neu-overexpressing primary tumour cells (Ova-1–Ova-5) were tested as effectors for cytotoxicity against T2 cells pulsed with the indicated HER-2/neu peptides. Effector to target ratio=40 : 1.
  2. bIndicates mean % cytotoxicity values from triplicate cultures. The s.d. (not shown) was always less then 15% of the mean values.
  3. cStatistically significant cytotoxic responses (P<0.01) over background responses (i.e. cytotoxicity against unpulsed T2 targets) and over cytotoxicity against control Melan (927) and gp (9154) peptides. Bold values indicate significance in comparison with control values.
Back to article page